Biotechnology Assets Valuation

Is BST undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BST when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BST's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BST's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BST?

Key metric: As BST is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BST. This is calculated by dividing BST's market cap by their current revenue.
What is BST's PS Ratio?
PS Ratio	6.2x
Sales	€3.37m
Market Cap	€19.81m

BST key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.4x
Enterprise Value/EBITDA	-12.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does BST's PS Ratio compare to its peers?

The above table shows the PS ratio for BST vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3.9x
ORY Oryzon Genomics	6.6x	62.8%	€99.4m
PHM Pharma Mar	7.7x	26.0%	€1.3b
LAB Labiana Health	0.2x	10.1%	€15.1m
GRF Grifols	1x	6.0%	€6.5b
BST Biotechnology Assets	6.2x	n/a	€19.8m

Price-To-Sales vs Peers: BST is expensive based on its Price-To-Sales Ratio (6.2x) compared to the peer average (3.9x).

Price to Sales Ratio vs Industry

How does BST's PS Ratio compare vs other companies in the European Biotechs Industry?

38 Companies	Price / Sales	Estimated Growth	Market Cap

38 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: BST is good value based on its Price-To-Sales Ratio (6.2x) compared to the European Biotechs industry average (7.9x).

Price to Sales Ratio vs Fair Ratio

What is BST's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BST PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	6.2x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BST's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.